Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $260,375.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the sale, the chief executive officer now directly owns 990,392 shares of the company’s stock, valued at approximately $20,629,865.36. This trade represents a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Enliven Therapeutics Stock Performance

ELVN stock opened at $20.92 on Friday. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -11.01 and a beta of 1.04. The firm has a 50-day simple moving average of $21.32 and a two-hundred day simple moving average of $23.76. Enliven Therapeutics, Inc. has a one year low of $15.96 and a one year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, BTIG Research began coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $38.25.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently modified their holdings of ELVN. Polar Capital Holdings Plc lifted its position in shares of Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after buying an additional 1,739,668 shares during the last quarter. Boxer Capital Management LLC purchased a new position in shares of Enliven Therapeutics in the 4th quarter valued at approximately $15,106,000. FMR LLC raised its position in shares of Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after purchasing an additional 601,611 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $8,199,000. Finally, Janus Henderson Group PLC raised its position in shares of Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after purchasing an additional 313,019 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.